Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Yau TCC, Lencioni R, Sukeepaisarnjaroen W, Chao Y, Yen CJ, Lausoontornsiri W, Chen PJ, Sanpajit T, Camp A, Cox DS, Gagnon RC, Liu Y, Raffensperger KE, Kulkarni DA, Kallender H, Ottesen LH, Poon RTP, Bottaro DP. Yau TCC, et al. Among authors: bottaro dp. Clin Cancer Res. 2017 May 15;23(10):2405-2413. doi: 10.1158/1078-0432.CCR-16-1789. Epub 2016 Nov 7. Clin Cancer Res. 2017. PMID: 27821605 Free PMC article. Clinical Trial.
Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. Linehan WM, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6282S-9S. doi: 10.1158/1078-0432.CCR-050013. Clin Cancer Res. 2004. PMID: 15448018 Review.
Targeting the c-Met signaling pathway in cancer.
Peruzzi B, Bottaro DP. Peruzzi B, et al. Among authors: bottaro dp. Clin Cancer Res. 2006 Jun 15;12(12):3657-60. doi: 10.1158/1078-0432.CCR-06-0818. Clin Cancer Res. 2006. PMID: 16778093 Review.
c-Met ectodomain shedding rate correlates with malignant potential.
Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP. Athauda G, et al. Among authors: bottaro dp. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4154-62. doi: 10.1158/1078-0432.CCR-06-0250. Clin Cancer Res. 2006. PMID: 16857786
Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.
Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K. Russo AL, et al. Among authors: bottaro dp. Clin Cancer Res. 2009 Jul 1;15(13):4292-8. doi: 10.1158/1078-0432.CCR-09-0599. Epub 2009 Jun 23. Clin Cancer Res. 2009. PMID: 19549766
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.
Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P. Jagoda EM, et al. Among authors: bottaro dp. J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23. J Nucl Med. 2012. PMID: 22917884 Free PMC article.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Choueiri TK, et al. Among authors: bottaro dp. J Clin Oncol. 2013 Jan 10;31(2):181-6. doi: 10.1200/JCO.2012.43.3383. Epub 2012 Dec 3. J Clin Oncol. 2013. PMID: 23213094 Free PMC article. Clinical Trial.
150 results